BACKGROUND: The aim was to investigate the outcomes associated with venous thromboembolism (VTE) among irresectable pancreatic cancer patients. METHODS: This is a follow-up study of consecutive irresectable cancer patients, treated and followed up in clinical trials between December 2001 and December 2004 in order to evaluate the prognostic impact of symptomatic VTE on clinical outcomes, such as response to treatment, progression-free survival (PFS) and overall survival (OS). RESULTS: Among 227 irresectable pancreatic cancer patients, with Eastern Cooperative Oncology Group performance status (ECOG-PS) < or = 2, 59 (26.0%) patients developed a VTE. A synchronous VTE occurred in 28 (12.3%) patients, while a VTE during chemotherapy was observed in 15 (6.6%) patients, and 16 (7.0%) patients experienced both events. Presence of synchronous VTE was associated with a higher probability of not responding to treatment (odds ratio 2.98, 95% CI 1.42-6.27, P = 0.004), but showed no effect on both PFS and OS at least at multivariate analysis. Occurrence of a VTE during chemotherapy showed a statistically significant effect on PFS (hazard ratio [HR] 2.59, 95% CI 1.69-3.97, P < 0.0001) and OS (HR 1.64, 95%CI 1.04-2.58, P = 0.032). CONCLUSIONS: Our data suggest that the occurrence of VTE may be associated with a reduced response rate and a shorter PFS and OS among patients with irresectable pancreatic cancer. In these patients the development of VTE may reflect the presence of a biologically more aggressive cancer that in turn leads to a worse prognosis.
BACKGROUND: The aim was to investigate the outcomes associated with venous thromboembolism (VTE) among irresectable pancreatic cancerpatients. METHODS: This is a follow-up study of consecutive irresectable cancerpatients, treated and followed up in clinical trials between December 2001 and December 2004 in order to evaluate the prognostic impact of symptomatic VTE on clinical outcomes, such as response to treatment, progression-free survival (PFS) and overall survival (OS). RESULTS: Among 227 irresectable pancreatic cancerpatients, with Eastern Cooperative Oncology Group performance status (ECOG-PS) < or = 2, 59 (26.0%) patients developed a VTE. A synchronous VTE occurred in 28 (12.3%) patients, while a VTE during chemotherapy was observed in 15 (6.6%) patients, and 16 (7.0%) patients experienced both events. Presence of synchronous VTE was associated with a higher probability of not responding to treatment (odds ratio 2.98, 95% CI 1.42-6.27, P = 0.004), but showed no effect on both PFS and OS at least at multivariate analysis. Occurrence of a VTE during chemotherapy showed a statistically significant effect on PFS (hazard ratio [HR] 2.59, 95% CI 1.69-3.97, P < 0.0001) and OS (HR 1.64, 95%CI 1.04-2.58, P = 0.032). CONCLUSIONS: Our data suggest that the occurrence of VTE may be associated with a reduced response rate and a shorter PFS and OS among patients with irresectable pancreatic cancer. In these patients the development of VTE may reflect the presence of a biologically more aggressive cancer that in turn leads to a worse prognosis.
Authors: João Godinho; Mafalda Casa-Nova; João Moreira-Pinto; Pedro Simões; Francisco Paralta Branco; Luísa Leal-Costa; Ana Faria; Fábio Lopes; José Alberto Teixeira; José Luís Passos-Coelho Journal: Oncologist Date: 2019-10-22
Authors: Yi Yang; Amanda Stang; Patrick G Schweickert; Nadia A Lanman; Erin N Paul; Brett P Monia; Alexey S Revenko; Joseph S Palumbo; Eric S Mullins; Bennett D Elzey; Edith M Janssen; Stephen F Konieczny; Matthew J Flick Journal: Cancer Res Date: 2019-05-02 Impact factor: 12.701
Authors: A A Khorana; C W Francis; K E Menzies; J-G Wang; O Hyrien; J Hathcock; N Mackman; M B Taubman Journal: J Thromb Haemost Date: 2008-09-15 Impact factor: 5.824
Authors: João Godinho; Mafalda Casa-Nova; João Moreira-Pinto; Pedro Simões; Francisco Paralta Branco; Luísa Leal-Costa; Ana Faria; Fábio Lopes; José Alberto Teixeira; José Luís Passos-Coelho Journal: Oncologist Date: 2019-10-22
Authors: F S Falvella; C Cremolini; R Miceli; F Nichetti; S Cheli; C Antoniotti; G Infante; A Martinetti; F Marmorino; E Sottotetti; R Berenato; M Caporale; A Colombo; F de Braud; M Di Bartolomeo; E Clementi; F Loupakis; F Pietrantonio Journal: Pharmacogenomics J Date: 2016-03-22 Impact factor: 3.550